| (Values in U.S. Thousands) | Sep, 2025 | Sep, 2024 | Sep, 2023 | Sep, 2022 | Sep, 2021 |
| Sales | 1,095 | 636 | 510 | 154 | 341 |
| Sales Growth | +72.17% | +24.71% | +231.17% | -54.84% | -25.22% |
| Net Income | -11,153 | -11,567 | -10,826 | -6,710 | -6,682 |
| Net Income Growth | +3.58% | -6.84% | -61.34% | -0.42% | -54.93% |
Oxford Biodynamics Plc (OBD.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Oxford BioDynamics PLC is a biotechnology company focused on advancing personalized healthcare through the development and commercialization of precision medicine tests for serious and impactful diseases. The company is engaged in the commercialisation of proprietary molecular diagnostics products and biomarker research and development. It has two commercially available products: the EpiSwitch PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch CiRT (Checkpoint Inhibitor Response Test) blood tests. The company generates revenue from the sales of proprietary products and biomarker research and development. Geographically, it generates the maximum revenue from the USA.
Fiscal Year End Date: 09/30